Dencatistat is in a phase 1 clinical clinical trial for the treatment of blood cancers where dencatistat could form the backbone of various treatment regimens with the potential for accelerated approval from a single arm phase 2 study. Dencatistat is in clinical trials for the treatment of solid tumours with a focus on lung and gynecological cancers (ovarian and endometrial) with the potential to become a therapy for multiple solid tumour types based on biomarker selection for loss of CTPS2.

Dencatistat is in a phase 2 clinical trial for the treatment of essential thrombocythaemia.